- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Systemic lupus erythematosus
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.9MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 1.2MB)
Anifrolumab – March 2024
Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL; Saphnelo®
Last updated
30 May 2025